Project Grant R43EY035861
- The National Eye Institute (NEI), part of the U.S. Department of Health and Human Services, awarded a $745,607 Project Grant under its Vision Research program (CFDA 93.867) to Retivue LLC, a company located in Virginia. The grant will support the development of the "Retivue Entire Eye" - a handheld, high-resolution, non-contact, wide-field retinal screening camera for premature and healthy newborn babies. This innovative device aims to overcome limitations of current retinopathy of...
- Federal Project Grant Award Summary The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded a $864,040 Project Grant to The Leland Stanford Junior University for research and development of an intraocular projector implant platform designed to restore vision in patients with severe corneal injuries. Awarded on July 1, 2025, with a completion date of June 30, 2030, this project addresses a critical clinical need for patients with corneal damage from...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $305,000 Project Grant to The Aird, effective September 1, 2025, through August 31, 2026, under the Vision Research program (CFDA 93.867). This project focuses on the development and commercialization of an Adaptive Optics Optical Coherence Tomography (AO-OCT) system designed for high-resolution, wide-field retinal imaging in rodent models, particularly mice. The deliverables include a portable AO-OCT imaging system...
- Federal Grant Award Summary Eye C Better Corp received a $315,825 Project Grant from the National Eye Institute (NIH) under the Vision Research program (CFDA 93.867), awarded September 1, 2025, with completion targeted for August 31, 2026. The company is developing Photonic Intraocular Pressure (IOP) Biomonitoring (PIB), a non-invasive, non-contact tonometry method that measures intraocular pressure using laser speckle pattern detection of sound wave-induced scleral oscillations. This technology...
- Federal Grant Award Summary Texas A&M University System Health Science Center received a $189,542 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective June 1, 2025 through January 31, 2028. The award supports the development and evaluation of optical coherence tomography (OCT)-guided ultrafast, nonthermal femtosecond laser microablation technology for non-invasive vitreoretinal surgery. This research addresses significant...
- Federal Grant Award Summary Surgical Vision Systems, Inc. received a $264,016 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) on June 1, 2025, for the development of a semi-autonomous, image-guided robotic suturing system. The company will design and develop a novel robotic surgery platform integrating optical coherence tomography (OCT) imaging with robotic microvascular suturing...
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded New York University School of Medicine a $673,747 Vision Research project grant (CFDA 93.867) commencing June 1, 2025, and concluding May 31, 2030, to develop advanced optical imaging technology for early detection of age-related macular degeneration (AMD). The research focuses on advancing visible-to-near-infrared spanning optical coherence tomography (OCT) to achieve half-micron axial resolution for retinal imaging,...
- Federal Project Grant Award Summary The National Eye Institute (Vision Research program, CFDA 93.867) awarded $437,250 to the University of California, San Diego, with an award date of September 1, 2025, and completion date of August 31, 2027. This R21 project grant supports the development of an integrated bioprinting and optogenetics platform designed to create a "visual-circuit-on-a-chip" for evaluating neural activity in stem cell-derived retinal disease models. The deliverables...
- F Square Medical LLC received a $880,668 Project Grant from the National Eye Institute of the National Institutes of Health, Department of Health and Human Services under the Vision Research federal grant program (CFDA 93.867) for the period of September 1, 2021 through August 31, 2022. The funding will support F Square Medical's development of the first-ever safe and effective anterior chamber paracentesis instrument to treat and diagnose ocular diseases. Specifically, the company will refine...
- This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $1,765,704 to Trustees of Boston University to develop an injectable optoacoustic retina prosthesis for high-precision retinal stimulation. The project aims to create a minimally invasive, soft, and biocompatible optoacoustic material that can be injected into targeted areas of the retina and stimulate it with micrometer-scale spatial resolution. The research team, led by Prof. Chen Yang, will develop...
RETIVUE ENTIREEYESCOPE: A HIGH RESOLUTION, TOP-DOWN VIEW, STEREO, ENDOSCOPIC VIEWING SYSTEM FOR VITREORETINAL SURGERY - PROJECT SUMMARY THERE ARE 300,000 VITREO-RETINAL PROCEDURES PERFORMED IN THE US EACH YEAR, WITH THE GOAL OF RESTORING VISION LOST FROM A MYRIAD OF RETINAL DISEASES INCLUDING RETINAL DETACHMENT, VITREOUS HEMORRHAGE, ENDOPHTHALMITIS, PRO- LIFERATIVE DIABETIC RETINOPATHY, AND OCULAR TRAUMA. THE TRADITIONAL SURGICAL APPROACH USES A TOP-DOWN WIDEFIELD VIEWING SYSTEM THRU THE CORNEA AND LENS TO BE ABLE TO VISUALIZE THE RETINA SUFFICIENTLY TO PERFORM NECESSARY FINE TISSUE MANIPULATION. DIFFICULTY ARISES WHEN THIS VIEW IS COMPROMISED DUE TO CORNEAL AND LENTICULAR OPACIFICA- TION, WHICH MAY PRECEDE ANY SURGICAL INTERVENTION OR ARISE DURING THE ATTEMPTED SURGICAL REPAIR ITSELF. UP TO 30% OF SURGERIES ENCOUNTER A COMPROMISED SURGICAL VIEW AND THIS DIRECTLY CORRESPONDS TO THE COMPLEXITY OF THE RETI- NAL PATHOLOGY AND DEPTH OF VISUAL LOSS FROM RETINAL DISEASE. FOR THE LAST 30 YEARS OPHTHALMIC ENDOSCOPY HAS BEEN AVAILABLE TO BYPASS AN OBSCURED ANTERIOR SEGMENT VIEW, BUT DESPITE THIS IT REMAINS POORLY UTILIZED. KEY REASONS FOR LOW ADOPTION RATES OF THIS TECHNOLOGY ALL STEM FROM THE NON-INTUITIVE VIEW THE ENDOSCOPE PROBE PROVIDES: SKEWED PERSPECTIVE, FLAT 2-D IMAGE, REDUCED FIELD OF VIEW, DIFFICULTY MAINTAINING PROBE ORIENTATION IN THE EYE, AND LACK OF CORRESPONDENCE BETWEEN SURGEON INSTRU- MENT HAND MOVEMENT AND WHAT IS SEEN ON SCREEN. THE IMAGE IS ALSO PROVIDED ON A SEPARATE SCREEN TO THE SIDE OF THE SURGICAL FIELD, AND THE CONSTANT NEED TO HOLD THE PROBE REMOVES THE CAPABILITY OF BI-MANUAL SURGERY. TO OVERCOME THESE HURDLES RETIVUE L.L.C. PROPOSES TO DEVELOP THE ENTIREEYESCOPE, THE FIRST 3-D STEREO ENDO- SCOPIC VIEWING SYSTEM TO PROVIDE A TRADITIONAL HEADS-UP, TOP-DOWN VIEW OF THE RETINA AS IF ONE IS LOOKING THRU A CLEAR CORNEA AND LENS. THIS WILL BE ACCOMPLISHED BY INSERTION OF TWO MINIATURE CAMERA MODULES THROUGH 20G SCLEROTOMIES, ENABLING 4X THE RESOLUTION OF CURRENT FIBER OPTIC BASED OPHTHALMIC ENDOSCOPES. ADVANCED IMAGE PROCESSING WILL TRANSFORM THE VIDEO STREAM FROM BOTH CAMERAS REAL-TIME INTO A STANDARD 3-D, ALWAYS IN FOCUS TOP-DOWN VIEW FOR THE SURGEON AS IF THEY WERE VISUALIZING THE RETINA THRU A CLEAR CORNEA AND LENS. THIS VIEW WILL BE COMPATIBLE WITH A VR HEADSET OR FEED INTO THE SURGICAL MICROSCOPE DIRECTLY. AN ENDOSCOPIC APPROACH THAT CLOSELY RECAPITULATES THE TRADITIONAL SURGEON VIEW SHOULD FACILITATE A GREATER RATE OF ADOPTION OF THIS TECHNOLOGY, AND ALLOWS FOR PRECISION MANIPULATION OF RETINAL TISSUE NOT AVAILABLE IN COMMER- CIALLY AVAILABLE DEVICES TO DATE. ULTIMATELY, THIS DEVICE WILL HELP IMPROVE SURGICAL OUTCOMES FOR PATIENTS, LEADING TO GREATER RECOVERY OF VISION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 1/12/26 | ||
| Not listed | $350.0k | 5/17/24 |